Something seems to work in Alzheimer’s – and it’s more blood than brain
Grifols has announced intriguing results in a subgroup of patients in a large Alzheimer's disease study, Ambar, but the finding could also benefit other suppliers of…
Cost-effectiveness doubts could hit Shire’s Takhzyro launch
A damning report by the US pricing watchdog Icer could bode ill for the uptake of Shire’s big hereditary angioedema hope.
Big biopharma back in favour in the third quarter
Several large-cap drug stocks registered healthy gains across the third quarter of 2018, signalling investors' growing confidence in biopharma after a disappointing…
The other shoe drops for Pharming
A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
Shire dodges pricing questions as lanadelumab’s big day nears
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?
Reasons to be cautious about new haemophilia therapies
Roche's Hemlibra has impressed, but uptake might not be as fast as some hope.
Why competitive bidding will be a hard task in Medicare
The US government is trying to change the way Medicare reimburses doctors for office-administered drugs – but whether it will succeed is another story.
Volatility returns for big biopharma
The downs are more pronounced than the ups as the macroeconomic climate turns against big pharma and biotech.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.